Dolutegravir: all 173 studies that test it

Page 2 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.Status unknownNCT03539224Phase 2
• Dual Obstructive Sleep Apnea TherapyStatus unknownNCT03435731Not applicable
• Phase 4 Study of Dolutegravir (DTG) in Russian FederationCompletedNCT03314064Phase 4
• Dolutegravir in Pregnant HIV Mothers and Their NeonatesCompletedNCT03249181Phase 3
• Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected SubjectsCompletedNCT03224338Phase 2
• A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy VolunteersStatus unknownNCT03199690Phase 1
• ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyCompletedNCT03122262Phase 3
• The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy VolunteersCompletedNCT03094507Phase 1
• Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownNCT03017872Phase 4
• National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionCompletedNCT02987530Phase 3
• Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV InfectionCompletedNCT02976259Phase 3
• Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing CureCompletedNCT02961829Not applicable
• Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible TabletCompletedNCT02893488Phase 1
• Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited SettingsCompletedNCT02777229Phase 3
• Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)CompletedNCT02741557Phase 1
• Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose CombinationsCompletedNCT02738931Phase 1
• A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176CompletedNCT02715479Phase 1
• Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject DrugsTerminatedNCT02659761Phase 4
• Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionActive, not recruitingNCT02656511Phase 4
• Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected PatientsTerminatedNCT02596334Phase 3
• A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed PatientsCompletedNCT02572947Phase 2
• Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenTerminatedNCT02566707Phase 2
• Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 InfectionStatus unknownNCT02551523Phase 2
• A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)CompletedNCT02527096Phase 2
• HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based RegimenCompletedNCT02513147Phase 4
• Dolutegravir Impact on Residual ReplicationCompletedNCT02500446Phase 4
• Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated ToxicityWithdrawnNCT02499978Phase 2/3
• Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal DiseaseCompletedNCT02487706Phase 4
• Dual Therapy With Boosted Darunavir + DolutegravirCompletedNCT02486133Phase 3
• The Dolutegravir Antiretroviral Mono-Therapy for HIV TrialCompletedNCT02401828Phase 4
• Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted DarunavirStatus unknownNCT02337322Phase 4
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyCompletedNCT02302547Phase 3
• Efavirenz to Dolutegravir Switch in Patients With CNS ToxicityStatus unknownNCT02285374Phase 4
• Dolutegravir Interactions With Artemisinin-based Combination TherapiesCompletedNCT02242799Phase 1
• SSAT061: PK of DTG and EVT/COBI in Healthy VolunteersCompletedNCT02219217Phase 1
• The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure ProphylaxisCompletedNCT02211690Phase 4
• Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot StudyCompletedNCT02211482Phase 4
• Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)CompletedNCT02098837Phase 4
• Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult SubjectsCompletedNCT02082808Phase 1
• Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)CompletedNCT02067767Phase 2
• Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult SubjectsCompletedNCT02064374Phase 1
• Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01967771Phase 1
• Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral DensityCompletedNCT01966822Phase 3
• Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamCompletedNCT01827540Phase 1
• Evaluation of the Bioequivalence of a Combined Formulated TabletCompletedNCT01622790Phase 1
• Dolutegravir Expanded Access StudyCompletedNCT01536873Not applicable
• Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and EthinylestradiolCompletedNCT01498861Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsCompletedNCT01467531Phase 1
• Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.CompletedNCT01467518Phase 1
• GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male SubjectsCompletedNCT01459315Phase 1
• Drug Interaction Study Between Dolutegravir and PrednisoneCompletedNCT01425099Phase 1
• GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female SubjectsCompletedNCT01404806Phase 1
• Relative Bioavailability Study of a Pediatric Granule Formulation of DolutegravirCompletedNCT01382238Phase 1
• Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination TabletsCompletedNCT01366547Phase 1
• Dolutegravir Renal Impairment StudyCompletedNCT01353716Phase 1
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese SubjectsCompletedNCT01332565Phase 1
• A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.WithdrawnNCT01283100Phase 1
• GSK1349572 Hepatic Impairment StudyCompletedNCT01231529Phase 1
• A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy SubjectsCompletedNCT01214993Phase 1
• GSK1349572 Drug Interaction Study With Fosamprenavir/RitonavirCompletedNCT01209065Phase 1
• GSK1349572 Drug Interaction Study With EfavirenzCompletedNCT01098526Phase 1
• GSK1349572 Relative Bioavailability StudyCompletedNCT01098513Phase 1
• Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT01068925Phase 1
• Study to Assess Cardiac Conduction of GSK1349572CompletedNCT00996021Phase 1
• GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose StudyCompletedNCT00942136Phase 1
• GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and AtazanavirCompletedNCT00883935Phase 1
• GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/RitonavirCompletedNCT00867152Phase 1
• A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572CompletedNCT00858455Phase 1
• GSK1349572 Drug Interaction Study With Protease InhibitorsCompletedNCT00774735Phase 1
• GSK1349572 Drug Interaction Study With EtravirineCompletedNCT00774111Phase 1
• GSK1349572 Drug Interaction With TenofovirCompletedNCT00726336Phase 1
• GSK1349572 Repeat Dose Escalation and Relative Bioavailability StudyCompletedNCT00631592Phase 1
• GSK1349572 First Time in Human StudyCompletedNCT00555035Phase 1

← Dolutegravir overview